Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Publication year range
1.
BJA Open ; 6: 100136, 2023 Jun.
Article in English | MEDLINE | ID: mdl-37588172

ABSTRACT

Background: Postoperative acute kidney injury (AKI) is a common complication and is associated with increased hospital length of stay and 30 day all-cause mortality. Unfortunately, we have neither a defined strategy to prevent AKI nor an effective treatment. In vitro, animal, and human studies have suggested that dexmedetomidine may have a renoprotective effect. We conducted a retrospective cohort study to evaluate if intraoperative dexmedetomidine was associated with a reduced incidence of AKI. Methods: We collected data from 6625 patients who underwent major non-cardiothoracic cancer surgery. Before and after propensity score matching, we compared the incidence of postoperative AKI in patients who received intraoperative dexmedetomidine and those who did not. AKI was defined according to the Kidney Disease Improving Global Outcomes (creatinine alone values) criteria and calculated for postoperative Days 1, 2, and 3. Results: Twenty per cent (n=1301) of the patients received dexmedetomidine. The mean [standard deviation] administered dose was 78 [49.4] mcg. Patients treated with dexmedetomidine were matched to those who did not receive the drug. Patients receiving dexmedetomidine had a longer anaesthesia duration than the non-dexmedetomidine group. The incidence of AKI was not significantly different between the groups (dexmedetomidine 8% vs no dexmedetomidine 7%; P=0.333). The 30 day rates of infection, cardiovascular complications, or reoperation attributable to bleeding were higher in patients treated with dexmedetomidine. The 30 day mortality rate was not statistically different between the groups. Conclusions: The administration of dexmedetomidine during major non-cardiothoracic cancer surgery is not associated with a reduction in AKI within 72 h after surgery.

2.
Rev. neuro-psiquiatr. (Impr.) ; 81(2): 95-102, abr. 2018. tab
Article in Spanish | LILACS-Express | LILACS | ID: biblio-1014366

ABSTRACT

El sistema vestibular permite estabilizar las imágenes visuales en la retina durante el desplazamiento y mantener el balance postural. Hay proyecciones desde los núcleos vestibulares hasta la corteza cerebral, específicamente a nivel del hipocampo y la región témporo-parietal, relacionadas a la llamada cognición espacial y a algunos procesos cognitivos no espaciales como atención y cálculo numérico. La presente es una revisión bibliográfica de areas de estudio e investigación en relación a estos procesos. En los sistemas de búsqueda Pub Med y Google Académico, se encontraron 44 artículos, de los cuales dos fueron capítulos de libros de texto. Se elaboran conclusiones pertinentes


The vestibular system allows the stabilization of visual images in the retina during displacement, thus contributing to the maintenance of postural balance. There are projections from the vestibular nuclei to the cerebral cortex, specifically hippocampus and the temporo-parietal region, related to the so-called spatial cognition and to some non- spatial cognitive processes such as attention and numerical calculation. A literature review on study and research areas related to these processes is presented. Academic Google and PubMed search engines were utilized with a total of 44 articles found, two of which were textbook chapters. Pertinent conclusions are elaborated.

3.
Methods Mol Biol ; 1372: 1-24, 2016.
Article in English | MEDLINE | ID: mdl-26530911

ABSTRACT

Monogenic skin diseases arise from well-defined single gene mutations, and in some cases a single point mutation. As the target cells are superficial, these diseases are ideally suited for treatment by nucleic acid-based therapies as well as monitoring through a variety of noninvasive imaging technologies. Despite the accessibility of the skin, there remain formidable barriers for functional delivery of nucleic acids to the target cells within the dermis and epidermis. These barriers include the stratum corneum and the layered structure of the skin, as well as more locally, the cellular, endosomal and nuclear membranes. A wide range of technologies for traversing these barriers has been described and moderate success has been reported for several approaches. The lessons learned from these studies include the need for combinations of approaches to facilitate nucleic acid delivery across these skin barriers and then functional delivery across the cellular and nuclear membranes for expression (e.g., reporter genes, DNA oligonucleotides or shRNA) or into the cytoplasm for regulation (e.g., siRNA, miRNA, antisense oligos). The tools for topical delivery that have been evaluated include chemical, physical and electrical methods, and the development and testing of each of these approaches has been greatly enabled by imaging tools. These techniques allow delivery and real time monitoring of reporter genes, therapeutic nucleic acids and also triplex nucleic acids for gene editing. Optical imaging is comprised of a number of modalities based on properties of light-tissue interaction (e.g., scattering, autofluorescence, and reflectance), the interaction of light with specific molecules (e.g., absorbtion, fluorescence), or enzymatic reactions that produce light (bioluminescence). Optical imaging technologies operate over a range of scales from macroscopic to microscopic and if necessary, nanoscopic, and thus can be used to assess nucleic acid delivery to organs, regions, cells and even subcellular structures. Here we describe the animal models, reporter genes, imaging approaches and general strategies for delivery of nucleic acids to cells in the skin for local expression (e.g., plasmid DNA) or gene silencing (e.g., siRNA) with the intent of developing nucleic acid-based therapies to treat diseases of the skin.


Subject(s)
Gene Transfer Techniques , Molecular Imaging/methods , Nucleic Acids/genetics , Skin/metabolism , Animals , Disease Models, Animal , Gene Expression , Genes, Reporter , Genetic Diseases, Inborn/genetics , Genetic Diseases, Inborn/therapy , Humans , Luminescent Measurements/methods , Mice , Mice, Transgenic , Microscopy/methods , Plasmids/administration & dosage , Plasmids/genetics , RNA, Small Interfering/genetics , Skin Diseases/genetics , Skin Diseases/therapy
4.
Mol Imaging Biol ; 18(1): 34-42, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26169581

ABSTRACT

PURPOSE: Small interfering RNAs (siRNAs) specifically and potently inhibit target gene expression. Pachyonychia congenita (PC) is a skin disorder caused by mutations in genes encoding keratin (K) 6a/b, K16, and K17, resulting in faulty intermediate filaments. A siRNA targeting a single nucleotide, PC-relevant mutation inhibits K6a expression and has been evaluated in the clinic with encouraging results. PROCEDURES: To better understand the pathophysiology of PC, and develop a model system to study siRNA delivery and visualize efficacy in skin, wild type (WT) and mutant K6a complementary DNAs (cDNAs) were fused to either enhanced green fluorescent protein or tandem tomato fluorescent protein cDNA to allow covisualization of mutant and WT K6a expression in mouse footpad skin using a dual fluorescence in vivo confocal imaging system equipped with 488 and 532 nm lasers. RESULTS: Expression of mutant K6a/reporter resulted in visualization of keratin aggregates, while expression of WT K6a/reporter led to incorporation into filaments. Addition of mutant K6a-specific siRNA resulted in inhibition of mutant, but not WT, K6a/reporter expression. CONCLUSIONS: Intravital imaging offers subcellular resolution for tracking functional activity of siRNA in real time and enables detailed analyses of therapeutic effects in individual mice to facilitate development of nucleic acid-based therapeutics for skin disorders.


Subject(s)
Gene Expression , Keratins/genetics , Molecular Imaging/methods , Mutant Proteins/metabolism , RNA, Small Interfering/metabolism , Repressor Proteins/metabolism , Skin/metabolism , Animals , Cell Line , Genes, Reporter , Green Fluorescent Proteins/metabolism , Humans , Injections, Intradermal , Keratins/metabolism , Mice , Mutation/genetics , Plasmids/metabolism , Protein Aggregates
5.
J Dermatol Sci ; 77(3): 156-65, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25656049

ABSTRACT

BACKGROUND: Pachyonychia congenita (PC) is a skin disorder resulting from mutations in keratin (K) proteins including K6a, K6b, K16, and K17. One of the major symptoms is painful plantar keratoderma. The pathogenic sequelae resulting from the keratin mutations remain unclear. OBJECTIVE: To better understand PC pathogenesis. METHODS: RNA profiling was performed on biopsies taken from PC-involved and uninvolved plantar skin of seven genotyped PC patients (two K6a, one K6b, three K16, and one K17) as well as from control volunteers. Protein profiling was generated from tape-stripping samples. RESULTS: A comparison of PC-involved skin biopsies to adjacent uninvolved plantar skin identified 112 differentially-expressed mRNAs common to patient groups harboring K6 (i.e., both K6a and K6b) and K16 mutations. Among these mRNAs, 25 encode structural proteins including keratins, small proline-rich and late cornified envelope proteins, 20 are related to metabolism and 16 encode proteases, peptidases, and their inhibitors including kallikrein-related peptidases (KLKs), and serine protease inhibitors (SERPINs). mRNAs were also identified to be differentially expressed only in K6 (81) or K16 (141) patient samples. Furthermore, 13 mRNAs were identified that may be involved in pain including nociception and neuropathy. Protein profiling, comparing three K6a plantar tape-stripping samples to non-PC controls, showed changes in the PC corneocytes similar, but not identical, to the mRNA analysis. CONCLUSION: Many differentially-expressed genes identified in PC-involved skin encode components critical for skin barrier homeostasis including keratinocyte proliferation, differentiation, cornification, and desquamation. The profiling data provide a foundation for unraveling the pathogenesis of PC and identifying targets for developing effective PC therapeutics.


Subject(s)
Keratins/genetics , Pachyonychia Congenita/genetics , RNA, Messenger/analysis , Transcriptome , Down-Regulation , Enzymes/genetics , Gene Expression Profiling , Humans , Keratin-16/genetics , Keratin-17/genetics , Keratin-6/genetics , Oligonucleotide Array Sequence Analysis , Pachyonychia Congenita/complications , Pain/genetics , Up-Regulation
6.
Mol Ther Nucleic Acids ; 2: e129, 2013 Oct 22.
Article in English | MEDLINE | ID: mdl-24150576

ABSTRACT

Despite the development of potent siRNAs that effectively target genes responsible for skin disorders, translation to the clinic has been hampered by inefficient delivery through the stratum corneum barrier and into the live cells of the epidermis. Although hypodermic needles can be used to transport siRNA through the stratum corneum, this approach is limited by pain caused by the injection and the small volume of tissue that can be accessed by each injection. The use of microneedle arrays is a less painful method for siRNA delivery, but restricted payload capacity limits this approach to highly potent molecules. To address these challenges, a commercially available motorized microneedle array skin delivery device was evaluated. This device combines the positive elements of both hypodermic needles and microneedle array technologies with little or no pain to the patient. Application of fluorescently tagged self-delivery (sd)-siRNA to both human and murine skin resulted in distribution throughout the treated skin. In addition, efficient silencing (78% average reduction) of reporter gene expression was achieved in a transgenic fluorescent reporter mouse skin model. These results indicate that this device effectively delivers functional sd-siRNA with an efficiency that predicts successful clinical translation.Molecular Therapy-Nucleic Acids (2013) 2, e129; doi:10.1038/mtna.2013.56; published online 22 October 2013.

7.
J Invest Dermatol ; 131(5): 1037-44, 2011 May.
Article in English | MEDLINE | ID: mdl-21248764

ABSTRACT

Although RNA interference offers therapeutic potential for treating skin disorders, delivery hurdles have hampered clinical translation. We have recently demonstrated that high pressure, resulting from intradermal injection of large liquid volumes, facilitated nucleic acid uptake by keratinocytes in mouse skin. Furthermore, similar intradermal injections of small interfering RNA (siRNA; TD101) into pachyonychia congenita (PC) patient foot lesions resulted in improvement. Unfortunately, the intense pain associated with hypodermic needle administration to PC lesions precludes this as a viable delivery option for this disorder. To investigate siRNA uptake by keratinocytes, an organotypic epidermal model, in which pre-existing endogenous gene or reporter gene expression can be readily monitored, was used to evaluate the effectiveness of "self-delivery" siRNA (i.e., siRNA chemically modified to enhance cellular uptake). In this model system, self-delivery siRNA treatment resulted in reduction of pre-existing fluorescent reporter gene expression under conditions in which unmodified controls had little or no effect. Additionally, treatment of PC epidermal equivalents with self-delivery "TD101" siRNA resulted in marked reduction of mutant keratin 6a mRNA with little or no effect on wild-type expression. These results indicate that chemical modification of siRNA may overcome certain limitations to transdermal delivery (specifically keratinocyte uptake) and may have clinical utility for inhibition of gene expression in the skin.


Subject(s)
Gene Expression Regulation , Keratin-6/antagonists & inhibitors , Pachyonychia Congenita/genetics , Pachyonychia Congenita/therapy , RNA, Small Interfering/therapeutic use , Cell Line , Genes, Reporter , Humans , Keratin-6/genetics , Keratinocytes/metabolism , Models, Biological , Skin/metabolism
8.
Mol Ther ; 18(9): 1667-74, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20571543

ABSTRACT

Despite rapid progress in the development of potent and selective small interfering RNA (siRNA) agents for skin disorders, translation to the clinic has been hampered by the lack of effective, patient-friendly delivery technologies. The stratum corneum poses a formidable barrier to efficient delivery of large and/or charged macromolecules including siRNAs. Intradermal siRNA injection results in effective knockdown of targeted gene expression but is painful and the effects are localized to the injection site. The use of microneedle arrays represents a less painful delivery method and may have utility for the delivery of nucleic acids, including siRNAs. For this purpose, we developed a loadable, dissolvable protrusion array device (PAD) that allows skin barrier penetration. The PAD tips dissolve upon insertion, forming a gel-like plug that releases functional cargo. PAD-mediated delivery of siRNA (modified for enhanced stability and cellular uptake) resulted in effective silencing of reporter gene expression in a transgenic reporter mouse model. PAD delivery of luciferase reporter plasmids resulted in expression in cells of the ear, back, and footpad skin as assayed by intravital bioluminescence imaging. These results support the use of PADs for delivery of functional nucleic acids to cells in the skin with an efficiency that may support clinical translation.


Subject(s)
Drug Carriers , Genes, Reporter/genetics , Plasmids/genetics , RNA, Small Interfering/physiology , Skin/metabolism , Animals , Female , Foot , Gene Silencing/physiology , Mice , Microscopy, Fluorescence , RNA, Small Interfering/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...